Skip to navigation Skip to content



National MS Society Invests in Commercial Research by Longevity Biotech for Development of a Neuroprotective/Repair Treatment for Progressive MS

November 3, 2017

The National MS Society, through Fast Forward, is investing up to $316,384 to enable Longevity Biotech, Inc. to evaluate LBT-3627 in laboratory models as a potential disease-modifying therapeutic agent for progressive multiple sclerosis. The program aims to determine the ability of LBT-3627 to protect and repair damaged nerve cells while also restoring balance to the immune system.
This investment stemmed from a request for proposals released by Fast Forward for projects focused on testing existing therapies or drug candidates to determine if they protect the nervous system from damage and/or repair damage, especially for the treatment of progressive MS.
“These preclinical studies may provide evidence for further development of LBT-3627 for progressive forms of MS.” said Mark Allegretta, PhD, Associate Vice President of Commercial Research at the National MS Society. “LBT-3627 has neuroprotective qualities and part of this work will determine its ability to promote maturation of myelin-producing cells.”
LBT-3627 is also in development for Parkinson’s disease among other neurological disorders.
Read More:
Read more about Fast Forward
Read more about research in progressive MS

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.